nick

[Serenity @aleabitoreddit]

FOCI (3363) is one of the most undervalued CPO players in the entire market right now at ~$3B.

Their BOM is massive relative to MC and they're expected to capture a dominant market share for $NVDA / $TSM.

You only start to see this show up 2027 / 2028, even though we're entering H2 2026 now (which is what I mean by frontrunning CPO supercycle).

[Serenity @aleabitoreddit]

If you don't remember:

$AEVA was my long for 4D Physical AI + World Models.

-> LG $50m in $AEVA to co-develop FMCW 4D LiDAR, explicitly citing Humanoids
-> LG (Boston Dynamics vision spuplier).

But...

Guess who makes those CW lasers for FM-CW Lidar?

The very same company for scaling photonics with 1.6T+ pluggables with $JBL to CPO in $MRVL Celestial.

Is the likely 4D AI CW laser supplier for humanoids and 4D physical AI.

One highly possible mapping:

-> $SIVE -> $AEVA -> $LG -> Boston Dynamics.

Both $SIVE and $AEVA were my two longs, but frontier sectors in 4D Physical AI to photonics tend to overlap.

[Serenity @aleabitoreddit]

Feels like people aren't articulating the bull case for $HIMS correctly:

Here's my view.

The main moat of $HIMS is network capture of retail audiences.

And the bull case is latent revenue monetization.

$HOOD achieved that same effect in fintech over 2025.

$META (fully grown) achieved that same effect in the social media sector over the past decade.

$HIMS is now at the starting point in 2026.

But given millions of new users across the globe (Europe, Australia, Japan, Canada) from Zava + Eucalyptus:

$HIMS now has that one-of-a-kind retail audience capture in the healthcare sector.

However, the difference between ~$70B companies in Robinhood and $1.6T giants in $META is that:

They've already successfully monetized their retail audiences both through margin optimization, and new revenue streams.

And very aggressively. $HIMS has not yet.

Robinhood did so by pushing new products from banking/credit cards/prediction markets/etc.

And they are all now independently generating $100m+ each as new revenue streams.

$META did so by capturing the maximum amount of revenue per user after acquiring WhatsApp/Instagram.

However, $HIMS has not gotten the chance to yet in the same way they did with the US (eg. Testosterone). Especially partially due to former lawsuits.

Now that's cleared up, the bull case can be seen again:

Instead of modeling what revenue Zava/Eucalyptus traditionally brought, the important thing to look at is retail network capture through # of people.

As this is biggest source of latent revenue + revenue projection beats not priced in.

Now, the billion dollar question is:

Will $HIMS end up like $HOOD?

$HIMS now has the one of the largest retail networks + distribution for healthcare.

However, cross-selling seems much harder in healthcare vs. fintech or social media channels.

The answer whether it ends up a $30B company or a $5B one is up for management to figure out.

So for people on the sideline, it might be worth flipping long again in the off-chance $HIMS manages to figure out latent revenue expansion from their new global userbase.

The ~40%+ short interest and the new $NVO partnership serves as a huge bonus as well.